Challenge
This Germany headquartered developer wanted to enter the UK market with a repurposed molecule (new form, new indication). They needed confirmation of the likely pricing window and volume forecast. They wanted advice on go-to-market and launch strategy and also the operational structure options to succeed in this less familiar, non-EU market.
Action
We reviewed prices, and usage, of the most comparable and widely used products to enable us to confirm the pricing proposal and forecast. Hawk Pharma Consulting presented NHS structure and function and from there presented the options, with pros and cons, for a range of operational models from own affiliate, through hybrid to partnering. This also provided the logic behind the proposed go-to-market and launch strategy.
Result
Hawk Pharma Consulting produced a comprehensive report for the client and provided it as a pre-read to a review meeting. They could make a decision on branding with the advice on prescribing habits and VPAG and this informed their regulatory application to MHRA. The client agreed the go-to-market and launch strategy. They have time to assess their operational options and the advice given will enable robust decisions.
Next Steps
As the MA process progresses the client can decide on their preferred operational model based on their preferred risk-reward balance for their business. If they choose to partner, we could establish the profile of an ideal partner and the exact partnership model and then work with the client to identify a shortlist and then assist in assessing them.
If you need support in assessing whether to, or how to, enter the UK please get in touch – info@hawkpharmaconsulting.com